NCT05560477View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2027

Conditions
Meniscus Tear
Interventions
DRUG

AM3101

Injectable drug product.

DRUG

Saline Placebo

2 mL 0.9% normal saline

Trial Locations (1)

45267

RECRUITING

University of Cincinnati, Cincinnati

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of Cincinnati

OTHER